R&D expense · 2021–2025
Immunocore Holdings R&D expense
$275M+23.7% · FY2025
Immunocore Holdings (IMCR) reported $275M in R&D expense for fiscal 2025, +23.7% year on year.
R&D expense — Research and development expense is what the company charged to R&D in the income statement for the year. Most companies report no R&D at all — the line is absent rather than zero — so this ranking covers the roughly 40% of filers that do.
Every row links to its own SEC filing · Fiscal year 2025 · Data as of September 25, 2026 · 2021–2025 compound annual growth +28.7%
R&D expense at companies of similar size
Cite this page
Ready-made references for the figures on this page, as published on September 25, 2026.
Wikipedia
{{cite web |title=Immunocore Holdings R&D expense |url=https://companiesranked.com/en/company/immunocore-holdings/research-and-development-expense |website=CompaniesRanked |date=2026-09-25 |language=en}}APA 7
CompaniesRanked. (September 25, 2026). Immunocore Holdings R&D expense. CompaniesRanked. https://companiesranked.com/en/company/immunocore-holdings/research-and-development-expenseBibTeX
@misc{companiesranked-en-company-immunocore-holdings-research-and-development-expense-2026,
author = {{CompaniesRanked}},
title = {{Immunocore Holdings R\&D expense}},
year = {2026},
howpublished = {\url{https://companiesranked.com/en/company/immunocore-holdings/research-and-development-expense}},
note = {Compiled from SEC EDGAR XBRL filings; data as of 2026-09-25},
urldate = {2026-09-25}
}The filing itself
The numbers above are read from this document: 10-K · 0001671927-26-000005 · February 25, 2026
{{cite web |title=Immunocore Holdings R&D expense — 10-K (0001671927-26-000005) |url=https://www.sec.gov/Archives/edgar/data/1671927/000167192726000005/imcr-20251231.htm |website=SEC EDGAR |publisher=U.S. Securities and Exchange Commission |date=2026-02-25}}The figures are rebuilt with every data refresh, so the reference carries the publication date. Add your own access date if your style requires one.